drugset / Trial / NCT00103766
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
Unknown
75 enrolled
O'Brien, Jeana D., MD, FACP, FCCP
Genentech, Inc. · collabScott and White Hospital & Clinic · collabScott, Sherwood and Brindley Foundation · collabTexas A&M University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline placebo.
Timeline
- Start
- 2004-10
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 4 mg | — |
| Subject | Alteplase | Protein / enzyme biologic | 10 mg | — |